Panc dose escalatio
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-jRCTs032210292
- Lead Sponsor
- Yamada Shigeru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
(1) Histologically or clinically diagnosed primary pancreatic tumor
(2) No indication for curative resection or no desire for surgery
(3) Has evaluable disease
(4) No obvious distant metastasis
(5) Age at the time of enrollment is 20 years or older
(6) Have a performance status (EGOG) of 0-2
(7) No prior surgical resection*1 or radiation therapy for pancreatic cancer
*1: Excluding simple laparotomy, gastrojejunostomy, and bile duct jejunal anastomosis
(8) Patients who are estimated to have a chance of survival for at least 3 months
(9) Patient's written consent for participation in the study has been obtained.
(1) Tumor involvement in the mucosal surface of the gastrointestinal tract
(2) A metal stent has been inserted.
(3) Active gastroduodenal ulcer is present
(4) Active and refractory infection in the irradiated area
(5) Patient has serious complications
(6) History of radiation therapy in the area
(7) It is judged that it is difficult to carry out this study for medical, psychological, or other reasons. Other reasons that the physician deems inappropriate for enrollment in this study
(8) Adult who lacks the capacity to give consent
(9) Eligible for the clinical trial of [A clinical trial for efficacy and safety on carbon-ion radiotherapy and concurrent GEM chemotherapy for locally advanced pancreatic cancer] (jRCT1031190131)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acute adverse reactions
- Secondary Outcome Measures
Name Time Method ate adverse reactions, local control rate, overall survival period
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.